13 & 14 January 2014
PARIS - Palais des Congrès

International Conference on the Management of Patients with Viral Hepatitis

Organised by Pr Patrick Marcellin

Organising Committee:
Tarik Asselah,
Nathalie Boyer, Olivier Lada, Michelle Martinot-Peignoux

Hôpital Beaujon, APHP - Université Paris-Diderot - INSERM CRB3

www.aphc.info
Dear colleagues,

Once again, in 2014 the 7th Paris Hepatitis Conference (PHC) will take place in January. The PHC is 10 years old!

As usual, the meeting will be a source of state of the art information on the management of patients with hepatitis B and hepatitis C presented by leading edge international experts who will proved the most recent data as well as their opinion on the clinical applications.

This year the meeting will summarize the spectacular recent progress made in the management of hepatitis C with new therapies. Today, triple therapy with telaprevir or boceprevir results in a cure in a high proportion (about 70%) of genotype 1 patients.

In 2014, new triple therapies with second generation protease inhibitors, polymerase inhibitors or NS5A inhibitors will be available in some countries. The advantages of these new treatments are considerable with better efficacy in all HCV genotypes, better tolerance and shorter treatment. However, these treatments will not be available in most countries.

A number of new drugs are under development with improved efficacy and tolerance. All clinicians are now focused upon an exciting new option: interferon free therapy. This perspective raises an important issue that will be at the heart of the discussions during the PHC 2014: which patients should be treated now and how to increase their chance of cure; which patients can wait to take advantage of future options?

The PHC 2014 will also spend a full day addressing important issues related to Hepatitis B. We will discuss the long-term efficacy and tolerance in patients receiving the most potent available antivirals. We also will address the usefulness of quantification of HBsAg as a new tool for predicting the severity of the disease and the response to therapy. The optimal management of special populations and difficult situations will be extensively discussed: co-infections, cirrhosis…

As in previous PHCs, interactive discussions and many specific working luncheons addressing the management of real-life patients will be privileged. Indeed, the ultimate goal of PHC 2014 is to review the most current knowledge and discuss their therapeutic applications with the best experienced experts to provide optimal therapy and the best chance of cure to as many patients as possible, worldwide.

I am looking forward to welcoming you in Paris.

Professor Patrick Marcellin
President of the 7th Paris Hepatitis Conference
HEPATITIS C

08.30  Introduction: Treatment of hepatitis C: are we almost at the end of the road?
  Patrick Marcellin (France)

08.45 - 09.15  State of the art lecture  Chairman: Tarik Asselah (France)
  ANRS: perspectives for basic research in viral hepatitis
  Jean-François Delfraissy (Director of ANRS, France)

09.15 - 10.30  How to optimize current therapy of G1 patients
  Chairpersons: Ira Jacobson (USA) and Masao Omata (Japan)
  09.15  Personalized treatment with telaprevir
         Graham Foster (UK)
  09:30  Personalized treatment with boceprevir
         Marc Bourlière (France)
  09.45  Is there still a role for PEG IFN+RBV therapy?
         Lawrence Serfaty (France)
  10:00  Round table discussion

10.30 - 11.00  Coffee break

11.00 - 12.00  How to optimize current therapy of non G1 patients
  Chairpersons: Graham Foster (UK) and Michael Manns (Germany)
  11.00  Genotype 2
         Adrian Gadano (Argentina)
  11.15  Genotype 3
         Stanislas Pol (France)
  11.30  Genotype 4
         Gamal Esmat (Egypt)
  11.45  Round table discussion

12.00 - 12.30  State of the art lecture and Award  Chairman: Patrick Marcellin (France)
  Milestones in viral hepatitis
  Christian Trépo (France)

12.30 - 14.30  Interactive Luncheons

14.30 - 15.45  Special populations
  Chairpersons: Sam Lee (Canada) and François Durand (France)
  14:30  Patients with cirrhosis
         Savino Bruno (Italy)
  14:45  Transplant patients
         Didier Samuel (France)
  15:00  HIV co-infected patients
         Douglas Dieterich (USA)
  15:15  Round table discussion

15:45 - 16:00  Coffee break

16.00 - 17.15  New therapeutic strategies
  Chairpersons: David Nelson (USA) and Stefan Zeuzem (Germany)
  16.00  Advantages of 2nd generation triple therapy
         Tarik Asselah (France)
  16.15  Protease, polymerase and NS5A inhibitors: what will be the winning combination?
         Raymond Schinazi (USA)
  16.30  Do we still need ribavirin?
         Mark Sulkowski (USA)
  16.45  Round table discussion

17.15 - 17.45  Controversy: F1/F2 patients: in 2014 treat now or still wait?
  Chairpersons: Eugene Schiff (USA) and Robert Flisiak (Poland)
  Treat now: Yves Benhamou (France)  Still wait: Mitchell Shiffman (USA)

17.45  Conclusion
  Patrick Marcellin (France)

18.00  Closing session

19.30  Congress dinner
HEPATITIS B

08.30  Introduction: HBV: Who, when and how to treat?  Patrick Marcellin (France)

08.40 - 10.00  The control of HBV related liver disease

Chairpersons: Henry Chan (Hong Kong) and Fabien Zoulim (France)

08.40  Regression of fibrosis. Is cirrhosis reversible?  Antonio Craxi (Italy)
08.55  Are non-invasive markers of fibrosis reliable?  Laurent Castera (France)
09.10  HBsAg quantitation: useful for staging the liver disease?  Maurizia Brunetto (Italy)
09.25  HBsAg quantitation: useful for the indication and follow-up of therapy?  Michelle Martinot-Peignoux (France)
09.40  Round table discussion

10.00 - 10.30  Coffee break

10.30 - 11.30  Optimal therapy of HBeAg-positive chronic hepatitis B

Chairpersons: Ji Dong Jia (China) and Michael Fried (USA)

10.30  Why do I treat my patient with a NUC?  Maria Buti (Spain)
10.45  Why do I treat my patient with pegylated IFN?  Jia-Horng Kao (Taiwan)
11.00  Round table discussion

11.30 - 12.30  Optimal therapy of HBeAg-negative chronic hepatitis B

Chairpersons: Seng Gee Lim (Singapore) and Feruccio Bonino (Italy)

11.30  Why do I treat my patient with a NUC?  Pietro Lampertico (Italy)
11.45  Why do I treat my patient with pegylated IFN?  George Papatheodoridis (Greece)
12.00  Round table discussion

12.30 - 14.30  Interactive Luncheons

14.30 - 16.30  New therapeutic perspectives

Chairpersons: Mario Rizzetto (Italy) and George Lau (Hong Kong)

14.30  New interferons and immunomodulators  Jake Liang (USA)
14.45  Impact of HBV therapy on the incidence of hepatocellular carcinoma  Massimo Colombo (Italy)
15.00  When to stop NUCs?  Rafael Esteban (Spain)
15.15  Round table discussion

15.45  Conclusion: tomorrow and after tomorrow?  Patrick Marcellin (France)

16.00  Closing session
### Programme of the Working Luncheons

For people not registered to the working luncheons, regular lunches are also organized in Salon Pont Neuf (Level 4).

| Room 241 - Level 2 | 1. The long term impact of treatment on the outcome of liver disease?  
Chair: Michael Fried (USA), Stefan Zeuzem (Germany)  
Speakers: Alessio Aghemo (Italy), Yazdan Yazdanpanah (France) |
|---|---|
| Room 251 - Level 2 | 2. First line therapy: interferon or analogues?  
Chair: Massimo Colombo (Italy)  
Speakers: George Lau (Hong Kong), Jorg Petersen (Germany) |
| Room 242 A - Level 2 | 3. Clinical applications of HBsAg quantification  
Chair: Henry Chan (Hong Kong)  
Speakers: Albert Tran (France), Denis Ouzan (France) |
| Room 242 B - Level 2 | 4. Staging of fibrosis: liver biopsy or indirect markers?  
Chair: Sam Lee (Canada)  
Víctor De Ledinghen (France)  
Speakers: Pierre Bedossa (France), Ana-Carolina Cardoso (Brazil) |
| Room 252 B - Level 2 | 5. Treatment of HCV cirrhosis and transplanted patients  
Chair: Didier Samuel (France), Dominique Valla (France)  
Speakers: Kosh Agarwal (UK), Rodolphe Sobesky (France) |
| Room 243 - Level 2 | 6. HIV-HCV coinfections  
Chair: Douglas Dieterich (USA), Ira Jacobson (USA)  
Speakers: Jürgen Rockstroh (Germany), Dominique Salmon (France) |
| Room 253 - Level 2 | 7. Interféron ou analogue ? (French speaking luncheon)  
Chair: Jean-Pierre Zarski (France), Philippe Sogni (France)  
Speakers: Najet Belhadj Brik (Tunisia), Raymond Sayegh (Lebanon) |
| Room 252 A - Level 2 | 8. Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon)  
Chair: Nathalie Boyer (France)  
Jean-François Cadranel (France), Mustapha Benazzouz (Morocco)  
Speakers: Adriana Popescu (Romania), Rachid Ould Gougam (Algeria) |
| Room 242 A - Level 2 | 1. How to optimize treatment in G1 naive patients?  
Chair: Antonio Craxi (Italy), Vlad Ratziu (France)  
Speakers: Vasily Isakov (Russia), Petr Urbánek (Czech Republic) |
| Room 242 B - Level 2 | 2. Resistance to DAAs: is this a real issue?  
Chair: Raymond Schinazi (USA), Philippe Mathurin (France)  
Speakers: Philippe Halfon (France), Olivier Lada (France) |
| Room 241 - Level 2 | 3. How to manage relapers and non-responders to PEG IFN + RBV therapy?  
Chair: Peter Ferenci (Austria), Andrzej Horban (Poland)  
Konstantin Zhdanov (Russia)  
Speakers: Maria Buti (Spain), Raymundo Parana (Brazil) |
| Room 251 - Level 2 | 4. Triple therapy with telaprevir or boceprevir: management of side effects  
Chair: Rafael Esteban (Spain)  
Markus Peck-Radosavljevic (Austria)  
Speakers: Thomas Berg (Germany), Robert Flisiak (Poland) |
| Room 252 B - Level 2 | 5. Future therapeutic strategies with direct acting antivirals  
Chair: Yves Benhamou (France), Massimo Levero (Italy)  
Speakers: Ola Weiland (Sweden), Mark Sulkowski (USA) |
| Room 243 - Level 2 | 6. How to optimize treatment in G4 patients?  
Chair: Tarik Asselah (France), Gamal Esmat (Egypt)  
Speakers: Imam Waked (Egypt), Vincent Leroy (France) |
| Room 253 - Level 2 | 7. Traitement des patients rechuteurs et non-répondeurs (French speaking luncheon)  
Chair: Christophe Hézode (France)  
Jean-Pierre Bronowicki (France)  
Speakers: Raluca Pais (France), Rodolphe Anty (France) |
| Room 252 A - Level 2 | 8. Comment optimiser le traitement des malades naïfs ? (French speaking luncheon)  
Chair: Daniel Dhumeaux (France), Mihai Voiculescu (Romania)  
Speakers: Vincent Di Martino (France), Nabil Debzi (Algeria) |
GENERAL INFORMATION

CONFERENCE DATES AND VENUE
From Monday 13th
to Tuesday 14th January 2014
At the “Palais des Congrès”
2, place de la Porte Maillot
75017 Paris – France
Metro and RER station:
“Porte Maillot”

CONFERENCE REGISTRATION DESK
13th & 14th January, from 7:30 am.
Welcome desks are organized on level 2 of
the Palais de Congrès in Foyer Bleu next to
the Amphithéâtre Bleu. You will be able to
register on site, retrieve your access badge,
george bag and proceedings.

CONGRESS OFFICE
Quadrate Santé / PHC 2014
43 rue des Tilleuls
92100 Boulogne-Billancourt
Phone: +33 1 41 10 46 65
Fax: +33 1 41 10 46 69
Contact: contact@phc-congress.com
www.aphc.info

CONGRESS HOTELS
Hyatt Regency Paris Étoile
3 place du Général Koenig
75017 Paris
Tel : +33 (0) 1 40 68 12 34
Méridien Etoile Hotel
81 boulevard Gouvion St-Cyr
75 017 Paris
Tel: +33 (0)1 40 68 34 34

CONGRESS DINNER
Monday 13th January at the
Pavillon d’Armenonville
Allée de Longchamp
75116 Paris
Buses will leave from the Palais des
Congrès at 7:30 p.m.
Dress code : cocktail attire

CME CONTINUOUS MEDICAL
EDUCATION ACCREDITATION
The “APHC” is accredited by the European
Accreditation Council for Continuing
Medical Education (EACCME) to provide
the following CME activity for medical
specialists.
The 7th Paris Hepatitis Conference is
designated for a maximum of (or “for up to”) 11 European CME credits (ECMEC).

LIVER INTERNATIONAL
The PHC Liver International Supplement is
available online at the following address:
http://blackwellpublishing.com

LUNCHES
2 types of lunches are organised
each day:
- Working Luncheons (Level 2).
The number of seats is limited.
- Regular luncheons are organised in
Salon Pont Neuf (Level 4).

METRO and RER
The metro station (line 1) and RER station
(line C) are located on level -1 of the
Palais des Congrès: Porte Maillot station.
The Conference will be held in
Amphitheatre Bleu on level 2.

OFFICIAL LANGUAGE
The official language
of the conference is English.

![Conference Venue Map](image-url)